Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $67.48 USD
Change Today -0.19 / -0.28%
Volume 5.2M
BMY On Other Exchanges
Symbol
Exchange
New York
Mexico
Frankfurt
As of 8:04 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

bristol-myers squibb co (BMY) Snapshot

Open
$67.87
Previous Close
$67.67
Day High
$68.08
Day Low
$67.34
52 Week High
05/20/15 - $69.86
52 Week Low
07/8/14 - $47.34
Market Cap
112.5B
Average Volume 10 Days
6.9M
EPS TTM
$1.51
Shares Outstanding
1.7B
EX-Date
07/1/15
P/E TM
44.6x
Dividend
$1.48
Dividend Yield
2.18%
Current Stock Chart for BRISTOL-MYERS SQUIBB CO (BMY)

bristol-myers squibb co (BMY) Details

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular. The company’s products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Erbitux, an IgG1 monoclonal antibody that targets and blocks the epidermal growth factor receptor; and Sprycel, a multi-targeted tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia. Its products also comprise Yervoy, a monoclonal antibody for the treatment of patients with metastatic melanoma; Abilify, an antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder, and major depressive disorder; Orencia for use in treating patients with moderately to severely active rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders. In addition, it is developing Opdivo, a human monoclonal antibody, which is in Phase III trials for non-small cell lung cancer, renal cell cancer, and melanoma; Beclabuvir, a non-nucleoside NS5B inhibitor that is in Phase III development for the treatment of HCV; Elotuzumab, a humanized monoclonal antibody, which is in Phase III trials for the treatment of multiple myeloma; and BMS-663068, an investigational compound that is being studied in HIV-1. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

25,000 Employees
Last Reported Date: 02/13/15
Founded in 1887

bristol-myers squibb co (BMY) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $916.0K
Executive Chairman, Officer, Ex-Officio Membe...
Total Annual Compensation: $1.7M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $910.5K
Chief Scientific Officer, Executive Vice Pres...
Total Annual Compensation: $875.0K
Executive Vice President, General Counsel and...
Total Annual Compensation: $849.8K
Compensation as of Fiscal Year 2014.

bristol-myers squibb co (BMY) Key Developments

Bristol-Myers Squibb Company Expands R&D Presence Within Hubs of World Class Science and Innovation

Bristol-Myers Squibb Company announced that the evolution of the company’s R&D organization, including plans to expand its presence within hubs of scientific excellence and innovation with the opening of a new research site in Cambridge, Mass. in addition to the ongoing expansion of the company’s R&D Discovery site in the San Francisco Bay Area. The new facility in Cambridge, which will be located at 100 Binney Street in Kendall Square, is expected to open in 2018. The ongoing site expansion in the San Francisco Bay Area adds 61,000 square feet of laboratory and office space at the Woodside Technology Park life science campus and is expected to be completed in 2016.

Portola Pharmaceuticals, Bristol-Myers Squibb Company and Pfizer Inc. Announce Full Results of Second Part of Phase 3 ANNEXA-A(TM) Study

Portola Pharmaceuticals, Bristol-Myers Squibb Company and Pfizer Inc. announced full results from the second part of the Phase 3 ANNEXA™-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of FXa Inhibitors – Apixaban) study. This registration-enabling study evaluated the safety and efficacy of andexanet alfa, an investigational antidote and U.S. Food and Drug Administration (FDA)-designated breakthrough therapy, administered as an intravenous (IV) bolus followed by a continuous two-hour infusion to sustain the reversal of anticoagulation activity of the Factor Xa inhibitor Eliquis (apixaban) in healthy volunteers ages 50-75 years. This second part of the study achieved all primary and pre-specified secondary endpoints with high statistical significance. Andexanet alfa produced rapid reversal of the anticoagulant effect of Eliquis, as measured by anti-Factor Xa activity, which was sustained for the duration of the infusion. Andexanet alfa significantly reduced the level of free unbound Eliquis in the plasma and restored thrombin generation to normal. Andexanet alfa was well tolerated, with no serious adverse events, thrombotic events, or antibodies to Factor X or Xa reported. Mild infusion reactions were reported in six subjects: four in the andexanet arm and two in the placebo arm. No subjects discontinued the study due to an adverse event. The full data set was presented in a Late-Breaking Clinical Trial oral session at the International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress in Toronto. Portola plans to submit data from the ANNEXA-A (apixaban) and ANNEXA-R (rivaroxaban) studies, and initial data from a Phase 4 study, as part of its Biologics License Application (BLA) to the FDA under an Accelerated Approval pathway by the end of 2015.

Bristol-Myers Squibb Company Announces European Commission Approves Opdivo

Bristol-Myers Squibb Company announced that the European Commission has approved Opdivo, a PD-1 immune checkpoint inhibitor, for the treatment of advanced (unresectable or metastatic) melanoma in adults, regardless of BRAF status. The approval allows for the marketing of Opdivo in all 28 Member States of the EU. It follows an accelerated assessment by the Committee for Medicinal Products for Human Use (CHMP), which was announced on April 24, 2015. This accelerated assessment was given because Opdivo qualified for the designation as a medicinal product of major interest from the point of view of public health and in particular from the view point of therapeutic innovation. Opdivo is the only PD-1 immune checkpoint inhibitor to receive an accelerated assessment in Europe, andis the first approval given by the European Commission for a PD-1 inhibitor in any cancer. The incidence of melanoma has continued to increase in almost all European countries, with an estimated one in five patients expected to develop metastatic, or advanced, disease. Historically, prognosis for late-stage metastatic melanoma has been poor: the average survival rate for stage IV is just six months with a one-year mortality rate of 75%.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BMY:US $67.48 USD -0.19

BMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $68.21 USD -0.30
Allergan plc $307.51 USD +0.60
Amgen Inc $153.26 USD -1.73
Medtronic PLC $73.81 USD -0.27
Novo Nordisk A/S kr368.70 DKK -2.20
View Industry Companies
 

Industry Analysis

BMY

Industry Average

Valuation BMY Industry Range
Price/Earnings 50.1x
Price/Sales 7.0x
Price/Book 7.2x
Price/Cash Flow 49.9x
TEV/Sales 6.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BRISTOL-MYERS SQUIBB CO, please visit www.bms.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.